Brainsway Ltd (BWAY)

$7.15

-0.22

(-2.99%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $7.08
    $7.58
    $7.15
    downward going graph

    1.01%

    Downside

    Day's Volatility :6.63%

    Upside

    5.67%

    downward going graph
  • $3.09
    $8.28
    $7.15
    downward going graph

    56.78%

    Downside

    52 Weeks Volatility :62.68%

    Upside

    13.65%

    downward going graph

Returns

PeriodBrainsway LtdIndex (Russel 2000)
3 Months
11.02%
0.0%
6 Months
20.17%
0.0%
1 Year
93.77%
0.0%
3 Years
-11.18%
-22.3%

Highlights

Market Capitalization
124.7M
Book Value
$1.43
Earnings Per Share (EPS)
0.02
PE Ratio
357.5
Wall Street Target Price
12.4
Profit Margin
1.67%
Operating Margin TTM
5.86%
Return On Assets TTM
0.73%
Return On Equity TTM
1.44%
Revenue TTM
36.4M
Revenue Per Share TTM
2.15
Quarterly Revenue Growth YOY
27.800000000000004%
Gross Profit TTM
20.0M
EBITDA
1.8M
Diluted Eps TTM
0.02
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.06
EPS Estimate Next Year
0.08
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.01

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Brainsway Ltd(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 73.43%

Current $7.15
Target $12.40

Company Financials

FY18Y/Y Change
Revenue
16.4M
↑ 47.12%
Net Income
-6.5M
↓ 8.15%
Net Profit Margin
-39.51%
↑ 23.78%
FY19Y/Y Change
Revenue
23.1M
↑ 40.89%
Net Income
-10.3M
↑ 59.41%
Net Profit Margin
-44.71%
↓ 5.2%
FY20Y/Y Change
Revenue
22.1M
↓ 4.52%
Net Income
-5.4M
↓ 47.86%
Net Profit Margin
-24.41%
↑ 20.3%
FY21Y/Y Change
Revenue
29.7M
↑ 34.46%
Net Income
-6.5M
↑ 20.0%
Net Profit Margin
-21.79%
↑ 2.62%
FY22Y/Y Change
Revenue
27.2M
↓ 8.36%
Net Income
-13.3M
↑ 106.58%
Net Profit Margin
-49.12%
↓ 27.33%
FY23Y/Y Change
Revenue
31.8M
↑ 16.96%
Net Income
-4.2M
↓ 68.56%
Net Profit Margin
-13.2%
↑ 35.92%
Q1 FY23Q/Q Change
Revenue
6.6M
↑ 9.81%
Net Income
-2.4M
↓ 37.13%
Net Profit Margin
-36.69%
↑ 27.41%
Q2 FY23Q/Q Change
Revenue
7.8M
↑ 18.17%
Net Income
-1.7M
↓ 31.59%
Net Profit Margin
-21.24%
↑ 15.45%
Q3 FY23Q/Q Change
Revenue
8.3M
↑ 6.04%
Net Income
-230.0K
↓ 86.17%
Net Profit Margin
-2.77%
↑ 18.47%
Q4 FY23Q/Q Change
Revenue
9.0M
↑ 8.76%
Net Income
127.0K
↓ 155.22%
Net Profit Margin
1.41%
↑ 4.18%
Q1 FY24Q/Q Change
Revenue
9.1M
↑ 0.73%
Net Income
111.0K
↓ 12.6%
Net Profit Margin
1.22%
↓ 0.19%
Q2 FY24Q/Q Change
Revenue
10.0M
↑ 10.01%
Net Income
600.0K
↑ 440.54%
Net Profit Margin
6.0%
↑ 4.78%
FY18Y/Y Change
Total Assets
23.6M
↓ 12.68%
Total Liabilities
16.7M
↑ 16.36%
FY19Y/Y Change
Total Assets
38.7M
↑ 64.12%
Total Liabilities
14.5M
↓ 12.82%
FY20Y/Y Change
Total Assets
34.0M
↓ 12.2%
Total Liabilities
14.4M
↓ 0.96%
FY21Y/Y Change
Total Assets
75.7M
↑ 122.67%
Total Liabilities
18.4M
↑ 28.04%
FY22Y/Y Change
Total Assets
64.5M
↓ 14.86%
Total Liabilities
19.1M
↑ 3.65%
FY23Y/Y Change
Total Assets
63.0M
↓ 2.33%
Total Liabilities
15.3M
↓ 19.74%
Q1 FY23Q/Q Change
Total Assets
62.0M
↓ 3.91%
Total Liabilities
19.0M
↓ 0.22%
Q2 FY23Q/Q Change
Total Assets
59.2M
↓ 4.37%
Total Liabilities
17.9M
↓ 6.02%
Q3 FY23Q/Q Change
Total Assets
59.8M
↑ 0.89%
Total Liabilities
18.6M
↑ 3.71%
Q4 FY23Q/Q Change
Total Assets
63.0M
↑ 5.35%
Total Liabilities
15.3M
↓ 17.47%
Q1 FY24Q/Q Change
Total Assets
65.1M
↑ 3.45%
Total Liabilities
17.3M
↑ 13.0%
Q2 FY24Q/Q Change
Total Assets
65.6M
↑ 0.75%
Total Liabilities
16.6M
↓ 4.28%
FY18Y/Y Change
Operating Cash Flow
-3.8M
↑ 8.83%
Investing Cash Flow
-1.1M
↓ 53.65%
Financing Cash Flow
-265.0K
↓ 102.39%
FY19Y/Y Change
Operating Cash Flow
-7.2M
↑ 92.0%
Investing Cash Flow
-2.4M
↑ 115.32%
Financing Cash Flow
22.5M
↓ 8580.75%
FY20Y/Y Change
Operating Cash Flow
-1.4M
↓ 80.18%
Investing Cash Flow
-2.5M
↑ 0.78%
Financing Cash Flow
-1.0M
↓ 104.58%
FY21Y/Y Change
Operating Cash Flow
884.0K
↓ 161.56%
Investing Cash Flow
-42.2M
↑ 1612.62%
Financing Cash Flow
41.5M
↓ 4130.68%
FY22Y/Y Change
Operating Cash Flow
-9.8M
↓ 1203.96%
Investing Cash Flow
42.2M
↓ 199.89%
Financing Cash Flow
-1.5M
↓ 103.73%
Q1 FY23Q/Q Change
Operating Cash Flow
-3.5M
↑ 57.94%
Investing Cash Flow
64.0K
↓ 85.01%
Financing Cash Flow
-66.0K
↓ 9.59%
Q2 FY23Q/Q Change
Operating Cash Flow
995.0K
↓ 128.1%
Investing Cash Flow
-1.5M
↓ 2460.94%
Financing Cash Flow
-377.0K
↑ 471.21%

Technicals Summary

Sell

Neutral

Buy

Brainsway Ltd is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Brainsway Ltd
Brainsway Ltd
4.84%
20.17%
93.77%
-11.18%
-31.9%
Stryker Corporation
Stryker Corporation
12.3%
0.36%
24.19%
28.8%
65.26%
Boston Scientific Corp.
Boston Scientific Corp.
10.6%
20.32%
51.42%
80.93%
95.5%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
9.4%
-28.78%
-12.2%
-45.23%
-7.73%
Abbott Laboratories
Abbott Laboratories
3.57%
-5.84%
13.1%
-11.32%
35.19%
Medtronic Plc
Medtronic Plc
10.85%
5.57%
12.46%
-33.2%
-16.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Brainsway Ltd
Brainsway Ltd
357.5
357.5
NA
0.06
0.01
0.01
NA
1.43
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Brainsway Ltd
Brainsway Ltd
Buy
$124.7M
-31.9%
357.5
1.67%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
65.26%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
95.5%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-7.73%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
35.19%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.71%
30.16
12.06%

Insights on Brainsway Ltd

  • Increasing Revenue

    Revenue is up for the last 8 quarters, 5.16M → 10.00M (in $), with an average increase of 8.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 111.0K → 600.0K (in $), with an average increase of 81.5% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 92.1%

Institutional Holdings

  • Masters Capital Management LLC

    5.40%

  • Phoenix Financial Ltd

    5.02%

  • Essex Investment Management Company, LLC

    2.08%

  • Dafna Capital Management LLC

    1.78%

  • Renaissance Technologies Corp

    1.67%

  • Acadian Asset Management LLC

    1.05%

Company Information

brainsway is a leading global neurmodulation company with headquarters in jerusalem and the us. our patented breakthrough technology has already treated over 10,000 patients, and has helped usher in a new era in brain disorder treatment. a non-invasive, yet highly effective solution for brain disorders, brainsway has helped thousands of patients across the world, from the unites states to europe to south america, and has the potential to make a difference in the well-being and health of millions of patients worldwide. brainsway's technology offers a much needed alternative for millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. brainsway's treatment has fda approval for treating patients with major depressive disorder*. the technology is safe, with no systemic or long-term side effects, in addition to being highly convenient, requiring only brief daily sessions over a few weeks. in addition to being used to treat depression daily

Organization
Brainsway Ltd
Employees
134
CEO
Mr. Hadar Levy
Industry
Medical Specialties

Discover More

FAQs